阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的临床疗效

目的 探讨阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症患者的临床疗效与安全性.方法 选取2013年5月至2014年2月收治的冠状动脉粥样硬化并高脂血症患者82例,根据就诊顺序随机分为单用组和联用组,每组41例.单用组采用阿托伐他汀钙治疗,20 mg/次,1次/d.联用组在此基础上加用依折麦布,10 mg/次,1次/d.比较两组治疗12周后降脂效果差异.结果 治疗前单用组与联用组总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、C反应蛋白(CRP)值无明显差异(P>0.05),治疗后两组TC、TG、LDL-C、CRP值较治疗前均显著降低,HDL-C显著增高(P<0.05),联用组较单用组变化更加显著(P<0.05).联用组LDL-C达标率(78.05%)显著高于单用组(53.66%)(P<0.05).两组治疗前后肝功能、肾功能指标变化差异无统计学意义(P>0.05).结论 阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的降脂效果更显著,同时不会加重肝肾负担.

Clinical efficacy of atorvastatincalcium combined with ezetimibe in the treatment of coronary atherosclerosis with hyperlipidemia

Objective To investigate the clinical efficiency and safety of atorvastatincalcium combined with ezetimibe for treating coronary atherosclerosis with hyperlipidemia. Methods A total of 82 cases of coronary atherosclerosis with hyperlipidemia treated in our hospital during May 2013 to Feb. 2014 were collected and divided into two groups. Patients in single drug group (n=41) were treated with atorvastatincalcium only, while patients in the combined drug group (n=41) received atorvastatincalcium and ezetimibe. After 12 weeks, lipid contents of the two groups were compared. Results Before the treatment, the values of TC, TG, HDL-C, LDL-C, and CRP in the two groups were not significantly different (P>0.05). After the treatment, the values of TC, TG, LDL-C, CRP in the two groups were markedly reduced and HDL-C was remarkably increased than before (P<0.05), and the improvement was greater in the combined drug group (P<0.05). The standard rate of LDL-C was 78.05% in combined drug group, which was notably higher than that of the single drug group (53.66%) (P<0.05). There were no differences in liver and renal function between the two groups before and after treatment (P>0.05). Conclusion Atorvastatincalcium combined with ezetimibe has significant lipid-lowering effect in treating coronary atherosclerosis with hyperlipidemia, and does not increase the burden on liver and kidney.